Fitriana Melysa, Hwang Wei-Lun, Chan Pak-Yue, Hsueh Tai-Yuan, Liao Tsai-Tsen
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Otorhinolaryngology Head and Neck Surgery Department, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.
Cancers (Basel). 2021 Apr 6;13(7):1742. doi: 10.3390/cancers13071742.
Head and neck squamous cell carcinomas (HNSCCs) are epithelial malignancies with 5-year overall survival rates of approximately 40-50%. Emerging evidence indicates that a small population of cells in HNSCC patients, named cancer stem cells (CSCs), play vital roles in the processes of tumor initiation, progression, metastasis, immune evasion, chemo-/radioresistance, and recurrence. The acquisition of stem-like properties of cancer cells further provides cellular plasticity for stress adaptation and contributes to therapeutic resistance, resulting in a worse clinical outcome. Thus, targeting cancer stemness is fundamental for cancer treatment. MicroRNAs (miRNAs) are known to regulate stem cell features in the development and tissue regeneration through a miRNA-target interactive network. In HNSCCs, miRNAs act as tumor suppressors and/or oncogenes to modulate cancer stemness and therapeutic efficacy by regulating the CSC-specific tumor microenvironment (TME) and signaling pathways, such as epithelial-to-mesenchymal transition (EMT), Wnt/β-catenin signaling, and epidermal growth factor receptor (EGFR) or insulin-like growth factor 1 receptor (IGF1R) signaling pathways. Owing to a deeper understanding of disease-relevant miRNAs and advances in in vivo delivery systems, the administration of miRNA-based therapeutics is feasible and safe in humans, with encouraging efficacy results in early-phase clinical trials. In this review, we summarize the present findings to better understand the mechanical actions of miRNAs in maintaining CSCs and acquiring the stem-like features of cancer cells during HNSCC pathogenesis.
头颈部鳞状细胞癌(HNSCC)是上皮性恶性肿瘤,其5年总生存率约为40%-50%。新出现的证据表明,HNSCC患者中的一小部分细胞,即癌症干细胞(CSC),在肿瘤起始、进展、转移、免疫逃逸、化学/放射抗性和复发过程中起着至关重要的作用。癌细胞获得干细胞样特性进一步为应激适应提供了细胞可塑性,并导致治疗抗性,从而导致更差的临床结果。因此,靶向癌症干性是癌症治疗的基础。已知微小RNA(miRNA)通过miRNA-靶标相互作用网络在发育和组织再生中调节干细胞特征。在HNSCC中,miRNA作为肿瘤抑制因子和/或癌基因,通过调节CSC特异性肿瘤微环境(TME)和信号通路,如上皮-间质转化(EMT)、Wnt/β-连环蛋白信号通路以及表皮生长因子受体(EGFR)或胰岛素样生长因子1受体(IGF1R)信号通路,来调节癌症干性和治疗效果。由于对疾病相关miRNA的更深入了解以及体内递送系统的进展,基于miRNA的治疗药物在人体中的给药是可行且安全的,在早期临床试验中取得了令人鼓舞的疗效结果。在本综述中,我们总结了目前的研究结果,以更好地理解miRNA在HNSCC发病机制中维持CSC和获得癌细胞干细胞样特征的机械作用。